ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3016% above fair value
$10.22+0.03 (+0.29%)
Close on Nov 12, 2026Market cap $92.82MP/E 51.1Yield –
ImmuCell operating margin
Operating margin is operating income as a percentage of revenue.
ImmuCell's operating margin for the twelve months ending Sep 30, 2026 was 14.5%. For fiscal 2025 it was 6.0%, against -6.2% the year before. The highest annual figure on record is 20.7% in fiscal 2015.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.0% | +12.2 |
| FY2024 | Dec 31, 2024 | -6.2% | +26.7 |
| FY2023 | Dec 31, 2023 | -32.9% | −20.5 |
| FY2022 | Dec 31, 2022 | -12.4% | −13.7 |
| FY2021 | Dec 31, 2021 | 1.3% | +10.3 |
| FY2020 | Dec 31, 2020 | -9.0% | −2.0 |
| FY2019 | Dec 31, 2019 | -7.0% | +6.2 |
| FY2018 | Dec 31, 2018 | -13.2% | −10.8 |
| FY2017 | Dec 31, 2017 | -2.3% | −11.7 |
| FY2016 | Dec 31, 2016 | 9.3% | −11.4 |
| FY2015 | Dec 31, 2015 | 20.7% | +23.5 |
| FY2014 | Dec 31, 2014 | -2.7% | −2.4 |
| FY2013 | Dec 31, 2013 | -0.3% | −4.9 |
| FY2012 | Dec 31, 2012 | 4.5% | +16.9 |
| FY2011 | Dec 31, 2011 | -12.4% | +3.4 |
| FY2010 | Dec 31, 2010 | -15.7% | −4.0 |
| FY2009 | Dec 31, 2009 | -11.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 11.9% | +11.5 |
| Q2 FY2026 | Jun 30, 2026 | 26.9% | +18.1 |
| Q1 FY2026 | Mar 31, 2026 | 19.0% | +5.2 |
| Q4 FY2025 | Dec 31, 2025 | -0.8% | −8.8 |
| Q3 FY2025 | Sep 30, 2025 | 0.4% | +9.9 |
| Q2 FY2025 | Jun 30, 2025 | 8.8% | +34.2 |
| Q1 FY2025 | Mar 31, 2025 | 13.9% | +18.0 |
| Q4 FY2024 | Dec 31, 2024 | 8.0% | +30.0 |
| Q3 FY2024 | Sep 30, 2024 | -9.6% | +27.4 |
| Q2 FY2024 | Jun 30, 2024 | -25.3% | +40.1 |
| Q1 FY2024 | Mar 31, 2024 | -4.1% | +37.6 |
| Q3 FY2023 | Sep 30, 2023 | -21.9% | −9.1 |
| Q2 FY2023 | Jun 30, 2023 | -36.9% | −20.9 |
| Q1 FY2023 | Mar 31, 2023 | -65.5% | −75.0 |
| Q4 FY2022 | Dec 31, 2022 | -41.8% | −44.4 |
| Q3 FY2022 | Sep 30, 2022 | -12.9% | −18.1 |
| Q2 FY2022 | Jun 30, 2022 | -16.0% | −20.8 |
| Q1 FY2022 | Mar 31, 2022 | 9.5% | +18.6 |
| Q4 FY2021 | Dec 31, 2021 | 2.7% | +19.6 |
| Q3 FY2021 | Sep 30, 2021 | 5.3% | +12.0 |
| Q2 FY2021 | Jun 30, 2021 | 4.7% | +28.1 |
| Q1 FY2021 | Mar 31, 2021 | -9.1% | −13.1 |
| Q4 FY2020 | Dec 31, 2020 | -16.9% | −10.3 |
| Q3 FY2020 | Sep 30, 2020 | -6.8% | +7.7 |
| Q2 FY2020 | Jun 30, 2020 | -23.3% | −3.1 |
| Q1 FY2020 | Mar 31, 2020 | 4.0% | −2.0 |
| Q4 FY2019 | Dec 31, 2019 | -6.7% | +24.9 |
| Q3 FY2019 | Sep 30, 2019 | -14.5% | −7.5 |
| Q2 FY2019 | Jun 30, 2019 | -20.2% | −13.8 |
| Q1 FY2019 | Mar 31, 2019 | 6.0% | +12.2 |
| Q4 FY2018 | Dec 31, 2018 | -31.5% | −18.3 |
| Q3 FY2018 | Sep 30, 2018 | -6.9% | +17.1 |
| Q2 FY2018 | Jun 30, 2018 | -6.4% | +8.7 |
| Q1 FY2018 | Mar 31, 2018 | -6.2% | −32.1 |
| Q4 FY2017 | Dec 31, 2017 | -13.2% | −18.6 |
| Q3 FY2017 | Sep 30, 2017 | -24.1% | – |
| Q2 FY2017 | Jun 30, 2017 | -15.2% | – |
| Q1 FY2017 | Mar 31, 2017 | 25.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 5.4% | – |
See a number that looks wrong?